Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer

S. De Placido, S. Tramontana, E. Ferrari, A. De Matteis, R. Lauria, F. Perrone, A. R. Bianco, C. Gallo, P. Ricchi, G. De Placido, S. Pignata, R. De Vivo, P. Silvestro, G. Landi, F. Nuzzo, G. Casella, F. Iodice, F. Tramontana, E. Varriale, A. V. LombardiR. Costanzo

Research output: Contribution to journalArticle

Abstract

Background: Prognosis of advanced ovarian cancer is unsatisfactory. Chemotherapy can be intensified combining active drugs at their highest possible doses. Patients and Methods. In this phase I/II trial, 77 untreated patients received escalating doses of paclitaxel (135, 155, 175, 195 and 215 mg/m2, infused over 3 hours) with carboplatin (AUC 3.6) and cisplatin (60 mg/m2). Nine, 16, 13, 8 and 3 patients were treated at the five levels, respectively. A further 28 patients were treated at the maximum tolerable dose (MTD). Results: Dose-limiting toxicities (one WHO grade 3 constipation, one grade 2 prolonged peripheral neurotoxicity and one grade 3 cardiac toxicity) occurred at 215 mg/m2 in 3 out of 3 patients. MTD was reached at level 4 paclitaxel dose (195 mg/m2). Response was evaluated in 62 patients. A complete response was achieved in 23 patients (37.1% - 95% CI 25.2-50.3), including 16 (25.8%) pathological and partial response in 28 (45.2%), for an overall response rate of 82.3% (95% exact CL: 70.5%-90.8%). The probability of response was affected by the degree of initial debulking (p=0.002) and not by the paclitaxel dose. In patients with stage III-IV disease, median progression-free survival was 17 months (95% CI 14-25). After a median follow-up of 28 months, median survival had not been reached; 2-year estimated survival was 67%. Conclusion: Paclitaxel can be safely given at the dose of 195 mg/m2 in combination with carboplatin (AUC 3.6) and cisplatin (60 mg/m2). This combination is active and safe and could be considered in clinical settings requiring intensive short treatment.

Original languageEnglish
Pages (from-to)4023-4030
Number of pages8
JournalAnticancer Research
Volume20
Issue number5 C
Publication statusPublished - 2000

Fingerprint

Carboplatin
Paclitaxel
Therapeutics
Cisplatin
Area Under Curve
Survival
TP protocol
Ovarian epithelial cancer
Constipation
Ovarian Neoplasms
Disease-Free Survival
Disease Progression
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Carboplatin
  • Chemotherapy
  • Cisplatin
  • Ovarian cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

De Placido, S., Tramontana, S., Ferrari, E., De Matteis, A., Lauria, R., Perrone, F., ... Costanzo, R. (2000). Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer. Anticancer Research, 20(5 C), 4023-4030.

Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer. / De Placido, S.; Tramontana, S.; Ferrari, E.; De Matteis, A.; Lauria, R.; Perrone, F.; Bianco, A. R.; Gallo, C.; Ricchi, P.; De Placido, G.; Pignata, S.; De Vivo, R.; Silvestro, P.; Landi, G.; Nuzzo, F.; Casella, G.; Iodice, F.; Tramontana, F.; Varriale, E.; Lombardi, A. V.; Costanzo, R.

In: Anticancer Research, Vol. 20, No. 5 C, 2000, p. 4023-4030.

Research output: Contribution to journalArticle

De Placido, S, Tramontana, S, Ferrari, E, De Matteis, A, Lauria, R, Perrone, F, Bianco, AR, Gallo, C, Ricchi, P, De Placido, G, Pignata, S, De Vivo, R, Silvestro, P, Landi, G, Nuzzo, F, Casella, G, Iodice, F, Tramontana, F, Varriale, E, Lombardi, AV & Costanzo, R 2000, 'Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer', Anticancer Research, vol. 20, no. 5 C, pp. 4023-4030.
De Placido S, Tramontana S, Ferrari E, De Matteis A, Lauria R, Perrone F et al. Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer. Anticancer Research. 2000;20(5 C):4023-4030.
De Placido, S. ; Tramontana, S. ; Ferrari, E. ; De Matteis, A. ; Lauria, R. ; Perrone, F. ; Bianco, A. R. ; Gallo, C. ; Ricchi, P. ; De Placido, G. ; Pignata, S. ; De Vivo, R. ; Silvestro, P. ; Landi, G. ; Nuzzo, F. ; Casella, G. ; Iodice, F. ; Tramontana, F. ; Varriale, E. ; Lombardi, A. V. ; Costanzo, R. / Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer. In: Anticancer Research. 2000 ; Vol. 20, No. 5 C. pp. 4023-4030.
@article{ae6956426cd847c09b28ccf95ed3fe11,
title = "Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer",
abstract = "Background: Prognosis of advanced ovarian cancer is unsatisfactory. Chemotherapy can be intensified combining active drugs at their highest possible doses. Patients and Methods. In this phase I/II trial, 77 untreated patients received escalating doses of paclitaxel (135, 155, 175, 195 and 215 mg/m2, infused over 3 hours) with carboplatin (AUC 3.6) and cisplatin (60 mg/m2). Nine, 16, 13, 8 and 3 patients were treated at the five levels, respectively. A further 28 patients were treated at the maximum tolerable dose (MTD). Results: Dose-limiting toxicities (one WHO grade 3 constipation, one grade 2 prolonged peripheral neurotoxicity and one grade 3 cardiac toxicity) occurred at 215 mg/m2 in 3 out of 3 patients. MTD was reached at level 4 paclitaxel dose (195 mg/m2). Response was evaluated in 62 patients. A complete response was achieved in 23 patients (37.1{\%} - 95{\%} CI 25.2-50.3), including 16 (25.8{\%}) pathological and partial response in 28 (45.2{\%}), for an overall response rate of 82.3{\%} (95{\%} exact CL: 70.5{\%}-90.8{\%}). The probability of response was affected by the degree of initial debulking (p=0.002) and not by the paclitaxel dose. In patients with stage III-IV disease, median progression-free survival was 17 months (95{\%} CI 14-25). After a median follow-up of 28 months, median survival had not been reached; 2-year estimated survival was 67{\%}. Conclusion: Paclitaxel can be safely given at the dose of 195 mg/m2 in combination with carboplatin (AUC 3.6) and cisplatin (60 mg/m2). This combination is active and safe and could be considered in clinical settings requiring intensive short treatment.",
keywords = "Carboplatin, Chemotherapy, Cisplatin, Ovarian cancer, Paclitaxel",
author = "{De Placido}, S. and S. Tramontana and E. Ferrari and {De Matteis}, A. and R. Lauria and F. Perrone and Bianco, {A. R.} and C. Gallo and P. Ricchi and {De Placido}, G. and S. Pignata and {De Vivo}, R. and P. Silvestro and G. Landi and F. Nuzzo and G. Casella and F. Iodice and F. Tramontana and E. Varriale and Lombardi, {A. V.} and R. Costanzo",
year = "2000",
language = "English",
volume = "20",
pages = "4023--4030",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 C",

}

TY - JOUR

T1 - Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer

AU - De Placido, S.

AU - Tramontana, S.

AU - Ferrari, E.

AU - De Matteis, A.

AU - Lauria, R.

AU - Perrone, F.

AU - Bianco, A. R.

AU - Gallo, C.

AU - Ricchi, P.

AU - De Placido, G.

AU - Pignata, S.

AU - De Vivo, R.

AU - Silvestro, P.

AU - Landi, G.

AU - Nuzzo, F.

AU - Casella, G.

AU - Iodice, F.

AU - Tramontana, F.

AU - Varriale, E.

AU - Lombardi, A. V.

AU - Costanzo, R.

PY - 2000

Y1 - 2000

N2 - Background: Prognosis of advanced ovarian cancer is unsatisfactory. Chemotherapy can be intensified combining active drugs at their highest possible doses. Patients and Methods. In this phase I/II trial, 77 untreated patients received escalating doses of paclitaxel (135, 155, 175, 195 and 215 mg/m2, infused over 3 hours) with carboplatin (AUC 3.6) and cisplatin (60 mg/m2). Nine, 16, 13, 8 and 3 patients were treated at the five levels, respectively. A further 28 patients were treated at the maximum tolerable dose (MTD). Results: Dose-limiting toxicities (one WHO grade 3 constipation, one grade 2 prolonged peripheral neurotoxicity and one grade 3 cardiac toxicity) occurred at 215 mg/m2 in 3 out of 3 patients. MTD was reached at level 4 paclitaxel dose (195 mg/m2). Response was evaluated in 62 patients. A complete response was achieved in 23 patients (37.1% - 95% CI 25.2-50.3), including 16 (25.8%) pathological and partial response in 28 (45.2%), for an overall response rate of 82.3% (95% exact CL: 70.5%-90.8%). The probability of response was affected by the degree of initial debulking (p=0.002) and not by the paclitaxel dose. In patients with stage III-IV disease, median progression-free survival was 17 months (95% CI 14-25). After a median follow-up of 28 months, median survival had not been reached; 2-year estimated survival was 67%. Conclusion: Paclitaxel can be safely given at the dose of 195 mg/m2 in combination with carboplatin (AUC 3.6) and cisplatin (60 mg/m2). This combination is active and safe and could be considered in clinical settings requiring intensive short treatment.

AB - Background: Prognosis of advanced ovarian cancer is unsatisfactory. Chemotherapy can be intensified combining active drugs at their highest possible doses. Patients and Methods. In this phase I/II trial, 77 untreated patients received escalating doses of paclitaxel (135, 155, 175, 195 and 215 mg/m2, infused over 3 hours) with carboplatin (AUC 3.6) and cisplatin (60 mg/m2). Nine, 16, 13, 8 and 3 patients were treated at the five levels, respectively. A further 28 patients were treated at the maximum tolerable dose (MTD). Results: Dose-limiting toxicities (one WHO grade 3 constipation, one grade 2 prolonged peripheral neurotoxicity and one grade 3 cardiac toxicity) occurred at 215 mg/m2 in 3 out of 3 patients. MTD was reached at level 4 paclitaxel dose (195 mg/m2). Response was evaluated in 62 patients. A complete response was achieved in 23 patients (37.1% - 95% CI 25.2-50.3), including 16 (25.8%) pathological and partial response in 28 (45.2%), for an overall response rate of 82.3% (95% exact CL: 70.5%-90.8%). The probability of response was affected by the degree of initial debulking (p=0.002) and not by the paclitaxel dose. In patients with stage III-IV disease, median progression-free survival was 17 months (95% CI 14-25). After a median follow-up of 28 months, median survival had not been reached; 2-year estimated survival was 67%. Conclusion: Paclitaxel can be safely given at the dose of 195 mg/m2 in combination with carboplatin (AUC 3.6) and cisplatin (60 mg/m2). This combination is active and safe and could be considered in clinical settings requiring intensive short treatment.

KW - Carboplatin

KW - Chemotherapy

KW - Cisplatin

KW - Ovarian cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=0034528762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034528762&partnerID=8YFLogxK

M3 - Article

C2 - 11268496

AN - SCOPUS:0034528762

VL - 20

SP - 4023

EP - 4030

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 C

ER -